CNR1 and Huntington disease: In 2008, a mouse model of Huntington's disease (HD) demonstrated a widespread impairment of endocannabinoid function.76 Subsequently, in the postmortem brains of human patients with HD,77 a striking loss of immunoreactivity of CB1 in putamen and globus pallidus was demonstrated throughout the time course of the disorder.